Treatment and survival rates for stage IV pancreatic cancer (ie, metastatic pancreatic cancer or MPC) have gone up during in the past 10 years, according to the results of a VA study published in the Journal of Gastrointestinal Oncology. The advent of new anti-neoplastic agents has boosted survival
“Despite the benefits of treatment, undertreatment of MPC remains an ongoing area of concern within the GI oncology community,” wrote authors, led by Ibrahim Azar, MD, Department of Internal Medicine, Albany Medical Center, Albany. Read more . . .